SCHEMBL3474652

SCHEMBL3474652

N#Cc1c(F)c(F)c(Br)c(F)c1F

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.33
ATM Q13315 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28966751 0.95 TRPV4 (0.31) TRPV4
SCHEMBL30165352 0.95 TRPV4 (0.31) TRPV4
SCHEMBL22579155 0.92 TRPV4 (0.30) TRPV4
SCHEMBL8346781 0.92 TRPV4 (0.32) TRPV4ATM
SCHEMBL5334905 0.89 TRPV4 (0.31) TRPV4
SCHEMBL20596085 0.88 TRPV4 (0.33) TRPV4ATM
SCHEMBL5333617 0.88 TRPV4 (0.33) TRPV4ATM
SCHEMBL20521848 0.86 TRPV4 (0.32) TRPV4ATM
SCHEMBL28966761 0.86 TRPV4 (0.32) TRPV4ATM
SCHEMBL57543 0.84 TRPV4 (0.41) TRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115745974-A Chiral near ultraviolet organic electroluminescent material, preparation method thereof and application thereof in CP-OLED 华南理工大学 2023-03-07 CN claimed
US-20260047341-A1 COMPOUND, LIGHT-EMITTING MATERIAL AND LIGHT-EMITTING ELEMENT KYULUX INC (JP) 2026-02-12 US disclosed
US-20250359476-A1 COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES KYULUX INC (JP) 2025-11-20 US disclosed
US-12369492-B2 Composition of matter for use in organic light-emitting diodes KYULUX, INC. (JP) 2025-07-22 US disclosed
CN-112786795-B Organic electroluminescent device and aromatic compound for organic electroluminescent device 三星显示有限公司 2025-06-24 CN disclosed
CN-119965341-A Electrolyte and battery 珠海冠宇电池股份有限公司 2025-05-09 CN disclosed
US-20250120247-A1 LIGHT EMITTING ELEMENT, POLYCYCLIC COMPOUND FOR THE SAME, AND DISPLAY DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2025-04-10 US disclosed
CN-119775282-A Light emitting element, polycyclic compound for light emitting element, and display device including light emitting element 三星显示有限公司 2025-04-08 CN disclosed
CN-112585778-B Organic light-emitting element, composition, and film 国立大学法人九州大学 2025-04-04 CN disclosed
EP-3587399-B1 COMPOUND, LIGHT-EMITTING MATERIAL AND LIGHT-EMITTING ELEMENT KYULUX INC (JP) 2025-03-05 EP disclosed
US-20070161626-A1 Substituted Indazoles, Compositions Containing The Same, And The Preparation And Use Thereof AVENTIS PHARMA S.A. (FR) 2007-07-12 US disclosed
EP-1765813-A1 SUBSTITUTED INDAZOLES, COMPOSITIONS CONTAINING SAME, PREPARATION AND USE Aventis Pharma S.A. (FR) 2007-03-28 EP disclosed
US-20060211739-A1 Use of selective P2X7 receptor antagonists ABBOTT LABORATORIES 2006-09-21 US disclosed
WO-2006086229-A1 THE USE OF SELECTIVE P2X7 RECEPTOR ANTAGONISTS ABBOTT LABORATORIES (US) 2006-08-17 WO disclosed
WO-2006003276-A1 SUBSTITUTED INDAZOLES, COMPOSITIONS CONTAINING SAME, PREPARATION AND USE AVENTIS PHARMA S.A. (FR) 2006-01-12 WO disclosed
US-6949579-B2 Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof AVENTIS PHARMA S.A. (FR) 2005-09-27 US disclosed
EP-1487804-A2 AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS Aventis Pharma S.A. (FR) 2004-12-22 EP disclosed
US-20040014802-A1 Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof AVENTIS PHARMA S.A. (FR) 2004-01-22 US disclosed
WO-2003078403-A2 DERIVES D’AMINOINDAZOLES COMME INHIBITEURS DE PROTEINE-KINASE AVENTIS PHARMA S.A. (FR) 2003-09-25 WO disclosed
US-5622137-A FOR USE IN TESTING COOKED FOODS TRANS WORLD SERVICES (US) 1997-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014802-A1 Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof CYP2C8, NR0B2, NR2C2 TRPV4 4168/4885ATM 3307/4885
US-20070161626-A1 Substituted Indazoles, Compositions Containing The Same, And The Preparation And Use Thereof CYP3A43, CYP3A7, CYP3A5 TRPV4 4396/4885ATM 1847/4885
US-20260047341-A1 COMPOUND, LIGHT-EMITTING MATERIAL AND LIGHT-EMITTING ELEMENT LBR, CTNND1, IK TRPV4 385/4885ATM 4119/4885
US-20060211739-A1 Use of selective P2X7 receptor antagonists P2RX1, P2RX3, P2RX7 TRPV4 92/4885ATM 4381/4885
US-20250359476-A1 COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES CRY2, SLCO1B3, NDUFV3 TRPV4 227/4885ATM 1817/4885
US-12369492-B2 Composition of matter for use in organic light-emitting diodes CRY2, SLCO1B3, NDUFV3 TRPV4 227/4885ATM 1817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.